Venetoclax plus rituximab for Waldenström’s macroglobulinemia
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 study tests whether the combination of venetoclax and rituximab works better for Waldenström’s macroglobulinemia (WM) than expected from standard approaches. It is for adults with WM who have symptoms or organ/health problems caused by the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and able to join the study willingly (sign informed consent).
- You must have a confirmed diagnosis of WM (tested on tissue samples within 4 months before starting treatment), and the study center must confirm it.
- You must have at least one WM-related problem such as fever/night sweats/weight loss/fatigue, swollen/bulky lymph nodes, high blood thickness, nerve symptoms, anemia/low platelets, kidney or amyloid problems, or high IgM/monoclonal protein levels.
- Your heart function must be good enough (left heart pumping strength—ejection fraction—about 40% or higher), and you must not have certain recent or unstable heart conditions.
- Your blood counts and organ tests must meet minimum levels (for example platelets and neutrophils above set thresholds; liver enzymes and bilirubin within limits; kidney filtration around 30 mL/min or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding venetoclax to rituximab works better than standard treatment options for Waldenstrom’s macroglobulinemia (WM). It’s for adults whose WM needs treatment and who meet specific blood, organ, infection, and medication safety requirements.
This trial tests a combination of three targeted drugs for people with untreated Waldenström's macroglobulinemia (WM), a rare blood cancer. The drugs aim to shrink tumors and lower the abnormal antibody (IgM) that causes symptoms, potentially offering a new first-line treatment option.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This trial compares two starting treatment plans for Waldenström’s macroglobulinaemia, testing whether one works better or causes fewer problems. It studies rituximab plus ibrutinib versus a standard mix of rituximab, cyclophosphamide, and dexamethasone (steroids).
This trial tests a combination of two targeted therapies for Waldenstrom macroglobulinemia that has come back or not responded to previous treatment. The combination aims to attack the cancer cells in two different ways and may be more effective than either drug alone.
This trial tests epcoritamab, an immunotherapy that helps your immune system attack cancer cells, for people with Waldenstrom macroglobulinemia (WM) whose disease has gotten worse or who couldn't tolerate previous treatments. It's for those who've already tried a BTK inhibitor (like ibrutinib or zanubrutinib) and an anti-CD20 antibody (like rituximab).
Hear when a new Waldenstrom Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.